These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15568893)

  • 61. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
    Wright JD; Tian C; Mutch DG; Herzog TJ; Nagao S; Fujiwara K; Powell MA
    Gynecol Oncol; 2008 Jun; 109(3):353-8. PubMed ID: 18407341
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size.
    Crass RL; Ross BE; Derstine BA; Lichty M; Sullivan JA; Su GL; Wang SC; Pai MP
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632017
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of Obesity on Hepatic Drug Clearance: What are the Influential Variables?
    Zhang T; Calvier EAM; Krekels EHJ; Knibbe CAJ
    AAPS J; 2024 May; 26(3):59. PubMed ID: 38724865
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass.
    Salazar DE; Corcoran GB
    Am J Med; 1988 Jun; 84(6):1053-60. PubMed ID: 3376975
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluating Lean Liver Volume as a Potential Scaler for
    Sinha J; Duffull SB; Green B; Al-Sallami HS
    Curr Drug Metab; 2020; 21(10):746-750. PubMed ID: 32410559
    [TBL] [Abstract][Full Text] [Related]  

  • 66. How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients.
    Bénézet S; Guimbaud R; Chatelut E; Chevreau C; Bugat R; Canal P
    Ann Oncol; 1997 Jun; 8(6):607-9. PubMed ID: 9261532
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours.
    Ortega A; Aldaz A; Giráldez J; Brugarolas A
    Pharm World Sci; 1999 Oct; 21(5):227-32. PubMed ID: 10550848
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Discontinuities and disruptions in drug dosage guidelines for the paediatric population.
    Chitty KM; Chan B; Pulanco CL; Luu S; Egunsola O; Buckley NA
    Br J Clin Pharmacol; 2018 May; 84(5):1029-1037. PubMed ID: 29411410
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism.
    Cerruti L; Bleyzac N; Tod M
    Clin Pharmacokinet; 2018 Jul; 57(7):831-841. PubMed ID: 28889370
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prediction of drug clearance in humans from laboratory animals based on body surface area.
    Liu XD; Chen J
    Eur J Drug Metab Pharmacokinet; 2001; 26(4):249-55. PubMed ID: 11808867
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Availability of information for dosing injectable medications in underweight or obese patients.
    Jacques KA; Erstad BL
    Am J Health Syst Pharm; 2010 Nov; 67(22):1948-50. PubMed ID: 21048212
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of a neural network approach with five traditional methods for predicting creatinine clearance in patients with human immunodeficiency virus infection.
    Herman RA; Noormohamed S; Hirankarn S; Shelton MJ; Huang E; Morse GD; Hewitt RG; Stapleton JT
    Pharmacotherapy; 1999 Jun; 19(6):734-40. PubMed ID: 10391419
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dofetilide Dose Reductions and Discontinuation in Obese Compared with Nonobese Patients.
    Anderson K; Greenlee K; Matteo M; Wilkoff B
    J Cardiovasc Pharmacol; 2022 Dec; 80(6):820-825. PubMed ID: 35976119
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Allometric size: The scientific theory and extension to normal fat mass.
    Holford NHG; Anderson BJ
    Eur J Pharm Sci; 2017 Nov; 109S():S59-S64. PubMed ID: 28552478
    [No Abstract]   [Full Text] [Related]  

  • 75. Mechanistic basis of using body size and maturation to predict clearance in humans.
    Anderson BJ; Holford NH
    Drug Metab Pharmacokinet; 2009; 24(1):25-36. PubMed ID: 19252334
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Which weight for weight-based dosage regimens in obese patients?
    Erstad BL
    Am J Health Syst Pharm; 2002 Nov; 59(21):2105-10. PubMed ID: 12434728
    [No Abstract]   [Full Text] [Related]  

  • 77. Should clearance be normalised to body surface or to lean body mass?
    Hallynck TH; Soep HH; Thomis JA; Boelaert J; Daneels R; Dettli L
    Br J Clin Pharmacol; 1981 May; 11(5):523-6. PubMed ID: 7272167
    [No Abstract]   [Full Text] [Related]  

  • 78. [An online tool to personalize the drug-doses for obese adults].
    Gouju J; Jourdan C; Legeay S
    Therapie; 2024; 79(3):379-392. PubMed ID: 37865563
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Improving Medication Dosing in the Obese Patient.
    Erstad BL
    Clin Drug Investig; 2017 Jan; 37(1):1-6. PubMed ID: 27599484
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Body surface area and body weight of Czech adult cancer population.
    Goněc R; Macků I; Iveta S; Kozáková Š
    Ceska Slov Farm; 2015 Dec; 64(6):264-8. PubMed ID: 27308665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.